Pyrazole

Pyrazole has become one of the most productive heterocyclic scaffolds in modern drug discovery, present in a growing number of FDA-approved therapeutics and appearing with increasing frequency in new drug approvals over the past decade. The rise of Pyrazole is unsurprising, with the scaffold's synthetic accessibility, drug-like properties, and ability to act as a bioisostere. The two adjacent nitrogen atoms create distinct electronic environments that allow the ring to participate in hydrogen bonding as both donor and acceptor, engage in dipole interactions with protein binding sites, and serve as a bioisostere for a range of other heterocycles including imidazole, isoxazole, and triazole. The flat, aromatic character of the ring supports productive π-stacking and hydrophobic burial within kinase hinge regions, while substitution at N-1, C-3, C-4, and C-5 provides extensive opportunities for structure-activity relationship exploration across diverse target families, and the ring's moderate lipophilicity and metabolic stability make it well suited for optimisation toward oral bioavailability.

Beyond kinase inhibition, pyrazole-containing compounds have demonstrated broad biological activity across anti-inflammatory, antifungal, antiviral, and CNS programmes, reflecting the scaffold's adaptability to a wide range of pharmacophoric requirements. Ruxolitinib (Jakafi, Incyte) is an FDA-approved first-in-class oral JAK1 and JAK2 inhibitor built around a pyrazolylpyrrolopyrimidine pharmacophore, first approved in 2011 as the first JAK inhibitor to receive FDA approval for any indication, indicated for intermediate and high-risk myelofibrosis. Pirtobrutinib (Jaypirca, Eli Lilly) is an FDA-approved first-in-class non-covalent reversible BTK inhibitor based on a 1-substituted pyrazole-4-carboxamide core, first approved in January 2023 for relapsed or refractory mantle cell lymphoma, representing a mechanistically distinct approach to BTK inhibition that retains activity in patients who have progressed on covalent BTK inhibitors.

Our range of Pyrazoles features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies. The full range can be found using the substructure feature of our Search tools.